Total medical costs of $16K for IFN-based antiviral tx for HCV
Raoel Maan, M.D., from the Erasmus MC University Medical Center in Rotterdam, Netherlands, and colleagues conducted a retrospective cohort study to examine the direct medical costs during IFN-based antiviral treatment and costs per SVR among patients with chronic HCV infection and biopsy-proven bridging fibrosis or cirrhosis. The study included 672 IFN-based treatments administered to 455 patients in five hepatology units of tertiary care centers in Europe and Canada.
The researchers found that the average total medical costs per patient were €14,559; with a mean cost per SVR of €38,514. Per SVR, the mean costs were €26,105 for patients with a normal platelet count, €50,907 for patients with thrombocytopenia, and €74,961 for patients with a platelet count below 100×109/L.
"Due to the lower SVR rates, the cost per SVR of IFN-based treatment increased when patients with more advanced liver disease were treated," the authors write. "Additional costs of IFN-free therapy could be limited among these patients."
Several authors disclosed financial ties to the pharmaceutical industry, including GlaxoSmithKline, which funded the study.
Full Text (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.